Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy

Calcified Tissue International

Volumn 66, Issue 3, 2000, Pages 195-199

  Fujita, T ^a   Satomura, A ^a   Hidaka, M ^a   Ohsawa, I ^a   Endo, M ^a   Ohi, H ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone mineral density; Deoxypyridinoline; Etidronate disodium; Glucocorticoid; Nephrotic syndrome

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; ETIDRONIC ACID; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PREDNISOLONE;

ADULT; AGING; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG MEGADOSE; FEMALE; HUMAN; LUMBAR SPINE; MALE; MENOPAUSE; NEPHROTIC SYNDROME; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; URINE LEVEL;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCIUM; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; OSTEOCALCIN; PHOSPHORUS; PREDNISOLONE; TIME FACTORS;

EID: 0033983726     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002230010039     Document Type: Article

References (24)

1. Reid IR (1989) Steroid osteoporosis. Calcif Tissue Int 45:63-72
2. Lukert BP, Raisz IG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 112: 352-364
3. Mcenery PT, Strife CE (1982) Nephrotic syndrome in childhood. Management and treatment in patients with minimal change disease, mesangial proliferation, or focal glomerulosclerosis. Pediatr Clin North Am 29:875-894
4. Han ZH, Palnitkar S, Rao DS, Nelson D, Farfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac cone: implications for mechanisms of bone loss. J Bone Miner Res 12:498-508
5. Grampp S, Genant HK, Mathur A, Lang P, Jergas M, Takada M, Glüer CC, Lu Y, Chavez M (1997) Comparisons of non-invasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res 12:697-711
6. Hall GM, Spector TD, Delmas PD (1995) Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 38:902-906
7. Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR (1998) Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 13:1283-1289
8. Fleisch H (1985) Bisphosphonate als Therapeutika-experimentelle Untersuchungen und klinische Anwendung. Ther Umschau 42:366-375
9. Reid IR, King AR, Alexander CJ, Ibbertson HK (1988) Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypyridine)-1,1-bisphosphonate (APD). Lancet i:143-146
10. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A, Boratto M, Gordon M, Steele M (1994) Intermittent cyclic therapy with etidronate in the prevention of corticosteroids-induced bone loss. J Rheumatol 21:1922-1926
11. Krolner B, Nielsen SP (1980) Measurement of bone mineral content (BMC) of the lumbar spine. I. Theory and application of a new two-dimensional dual-photon attenuation method. Scand J Clin Lab Invest 40:653-663
12. Taussky HH (1954) A microcolorimetric determination of creatinine in urine by the Jaffe reaction. J Biol Chem 208:853-861
13. Price PA, Baukol SA (1980) 1,25-Dihydroxyvitamin D3 increases synthesis of the vitamin k-dependent bone protein by osteosarcoma cells. J Biol Chem 255:11660-11663
14. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD ( 1992) Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res 7:1389-1398
15. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ (1991) Evaluation of urinary hydroxypyridinium crosslink measurements as a specific marker in metabolic bone diseases. Eur J Clin Invest 21:310-315
16. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 9:1643-1649
17. Connerty HV, Briggs AR (1966) Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol 45:290-296
18. Drewes PA (1972) Direct colorimetric determination of phosphorus in serum and urine. Clin Chim Acta 39:81-88
19. The committee on enzymes of The Scandinavian Society for Clinical Chemistry and Clinical Physiology (1974) Recommended methods for the determination of four enzymes in blood. Scan J Clin Lab Invest 33:291-306
20. Fukase M, Fujita T, Matsumolo T, Ogata E, Iijima T, Takezawa J, Saito K (1989) Clinical studies using a highly sensitive radioimmunoassay for mid-region and carboxy terminus of parathyroid hormone in normal hypo-and hypercalcemic states. Folia Endocrinol 65:807-827
21. Roux C, Oriente P, Laan R, Hughes RA, Inner J, Goemaere S, Di Munno O, Pouilles MJ, Horlait S, Cortet B, for THe Ciblos Study Group (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:1128-1133
22. Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235-242
23. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lintle B, Olszynski W, Ste.-Marie L-G, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
24. Mulder H, Struys A (1994) Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348-350